Peripheral Kynurenine Pathway Metabolites in Patients with Psoriasis
International Journal of Molecular Sciences · 28.03.2025 · 26 (7) · 3139
DOI: 10.3390/ijms26073139 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.03.2025. Verfasst von Anna Stepaniuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Medical University of Bialystok, Zurawia 14, 15-540 Bialystok, Poland. Hauptthemen laut MEDLINE: Kynurenine, Psoriasis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Bialystok, Poland.
Abstract (Originalsprache)
Psoriasis is a systemic disease affecting 2–3% of the general population. Tryptophan (TRP) is an amino acid metabolized in the kynurenine pathway (KP). The aim of this study was to assess the kynurenine pathway’s metabolites in serum and urine of psoriatic patients and explore the possible interplay with the disease’s pathogenesis and its comorbidities. The study involved 60 patients with plaque psoriasis and 30 healthy volunteers matched for gender, age, and BMI. Serum and urine samples were taken from the participants and tested for TRP, indoleamine 2,3-dioxygenase (IDO), 2,3-tryptophan dioxygenase (TDO), kynurenine (KYN), kynurenic acid (KYNA), quinolinic acid (QUIN), and numerous laboratory parameters. Correlations between the metabolites’ levels and clinical, laboratory parameters and depression occurrence were statistically evaluated. Concentrations of tryptophan, kynurenic acid, and quinolinic acid in serum and urine were significantly higher among patients with psoriasis (p < 0.05 and p < 0.001, p < 0.05 and p < 0.05 and p < 0.001 and p < 0.001, respectively). A significant stimulation of the kynurenine pathway in serum and urine of patients with psoriasis suggests its role in its pathogenesis and interplay between chronic inflammation or comorbidities. Further research is needed to discover whether the increase in KP metabolites is an indicator of inflammation or a compensatory mechanism in psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Medical University of Bialystok, Zurawia 14, 15-540 Bialystok, Poland.
- Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C, 15-089 Bialystok, Poland.
- Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C, 15-089 Bialystok, Poland.
ORCID-Profile: Anna Stepaniuk, Anna Baran, Justyna Magdalena Hermanowicz, Dariusz Pawlak, Iwona Flisiak
Förderung
- Medical University of Bialystok, Poland
Zitieren
APA
Stepaniuk, A., Baran, A., Hermanowicz, J. M., Sieklucka, B., Pawlak, D., & Flisiak, I. (2025). Peripheral Kynurenine Pathway Metabolites in Patients with Psoriasis. International Journal of Molecular Sciences, 26(7), 3139. https://doi.org/10.3390/ijms26073139
Vancouver
Stepaniuk A, Baran A, Hermanowicz JM, Sieklucka B, Pawlak D, Flisiak I. Peripheral Kynurenine Pathway Metabolites in Patients with Psoriasis. International Journal of Molecular Sciences. 2025;26(7):3139. doi:10.3390/ijms26073139
BibTeX
@article{Stepaniuk2025,
author = {Stepaniuk, Anna and Baran, Anna and Hermanowicz, Justyna Magdalena and Sieklucka, Beata and Pawlak, Dariusz and Flisiak, Iwona},
title = {Peripheral Kynurenine Pathway Metabolites in Patients with Psoriasis},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {7},
pages = {3139},
doi = {10.3390/ijms26073139}
}
EUVIMED